Just finished reading the report, and I particularly liked: "The results from 3 pre-chemotherapy participants who received 8 GBq of 67Cu-SAR-bisPSMA have been outstanding with a favourable safety profile and excellent efficacy, where PSA reductions were greater than 80% for all participants and above 95% for 2 out of the 3 participants, with all of them achieving radiographic disease control and 1 showing a complete response to date. "
What seems interesting to me, perhaps mistakenly, is that the key may be to have (a goal of) all patients being treated with CU67 as the first, and hopefully the only, treatment needed ongoing. Avoidance of Chemo and ADT has to be a huge bonus for patients, I believe.
CU6 Price at posting:
$3.13 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)